Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced that Chairman and CEO Leonard Mazur will present at the ThinkEquity Conference on October 26, 2022, at 1:00 PM ET, in New York City. The conference will focus on the company's late-stage biopharmaceutical developments, including Mino-Lok® and I/ONTAK, aimed at treating critical health conditions. Investors can register to view the live presentation and are encouraged to request one-on-one meetings through the conference platform.
- None.
- None.
CRANFORD, N.J., Oct. 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will be presenting at the ThinkEquity Conference on October 26, 2022.
Conference Details:
Date: | October 26, 2022 |
Time: | 1:00PM ET |
Location: | The Mandarin Oriental Hotel in New York, New York |
Live presentation: | Viewers must register for the conference to view the live presentation. |
Webcast replay: | Available for the following 90 days on the Company's Investors website. |
One-on-one Meetings: | Investors may request meetings online upon registration. |
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company's diversified pipeline includes two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), for which a BLA has been submitted. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). In the first half of 2022, Citius initiated a Phase 2b trial for Halo-Lido, a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.
Investor Contact:
Ilanit Allen
Vice President, Corporate Communications and Investor Relations
T: 908-967-6677 x113
E: ir@citiuspharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-thinkequity-conference-on-october-26-2022-301651872.html
SOURCE Citius Pharmaceuticals, Inc.
FAQ
What is the date of Citius Pharmaceuticals' presentation at the ThinkEquity Conference?
Who is presenting for Citius Pharmaceuticals at the conference?
What time will Citius Pharmaceuticals' presentation take place?
Where is the ThinkEquity Conference being held?
How can I watch the Citius Pharmaceuticals presentation live?
Will there be a replay of the Citius Pharmaceuticals presentation?
